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Prescribers’ satisfaction with delivering
medications for opioid use disorder
Hannah K. Knudsen1*, Randy Brown2, Nora Jacobson3, Julie Horst4, Jee-Seon Kim5, Hanna Kim5, Lynn M. Madden6,
Eric Haram7 and Todd Molfenter4
Abstract
Background: Expanding access to medications for opioid use disorder (MOUD), such as buprenorphine and
extended release (XR) naltrexone, is critical to addressing the US opioid epidemic, but little is known about
prescriber satisfaction with delivering these two types of MOUD. The current study describes the satisfaction of
prescribers delivering buprenorphine and XR-naltrexone while examining whether satisfaction is associated with
current patient census and organizational environment.
Methods: As part of a cluster randomized clinical trial (RCT) focused on expanding access to medication for opioid
use disorder, 41 MOUD prescribers in Florida, Ohio, and Wisconsin completed a web-based survey. The survey
included measures of prescriber satisfaction with delivering buprenorphine treatment and XR-naltrexone. In
addition, the survey measured several prescriber characteristics and their perceptions of the organizational
environment.
Results: Prescribers were generally satisfied with their work in delivering these two types of MOUD. Prescribers
reporting a greater number of patients (r = .46, p = .006), those who would recommend the center to others (r =
.56, p < .001), and those reporting positive relationships with staff (r = .56, p < .001) reported significantly greater
overall satisfaction with delivering buprenorphine treatment. Prescribers who more strongly endorsed feeling
overburdened reported lower overall buprenorphine satisfaction (r = -.37, p = .02). None of the prescriber
characteristics or perceptions of the organizational environment were significantly associated with overall
satisfaction with delivering XR-naltrexone treatment.
Conclusions: The generally high levels of satisfaction with both types of MOUD is notable given that prescriber
dissatisfaction can lead to turnover and impact intentions to leave the profession. Future research should continue
to explore the prescriber characteristics and organizational factors associated with satisfaction in providing different
types of MOUD.
Registration: ClinicalTrials.gov. NCT02926482. Date of registration: September 9, 2016. https://clinicaltrials.gov/ct2/
show/NCT02926482.
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Background
The US opioid epidemic continues to be a major public
health problem, resulting in nearly 450,000 deaths from
1999 to 2018 [1], with concerns growing amid early evi-
dence that the COVID-19 pandemic is worsening this
crisis [2–4]. Limited access to evidence-based treatment,
particularly medications for opioid use disorder
(MOUD) [5, 6], continues to be a significant challenge
despite efforts to expand treatment access [7–9]. If ac-
cess to MOUD is to expand in the US, it is critically im-
portant to continue to expand the number of medical
professionals who are willing to prescribe buprenorphine
and extended-release naltrexone (XR-naltrexone). Al-
though the number of medical professionals who have
the capacity to prescribe buprenorphine continues to
grow [10–13], recent data indicate that only half of waiv-
ered prescribers have any patients receiving buprenor-
phine and that median monthly census is considerably
lower than the cap on patients, even among those hold-
ing the 275-patient waiver [14]. Utilization of XR-
naltrexone is even lower than buprenorphine [15], par-
ticularly in primary care [16].
An understudied issue is prescriber satisfaction with
delivering these two types of MOUD. A systematic re-
view published by Becker and Fiellin in 2005 [17] noted
a gap in the literature regarding prescriber satisfaction
with delivering buprenorphine treatment. Since that re-
view, there have been two publications regarding pre-
scriber satisfaction, one a qualitative study of rural
prescribers [18] and the other a survey of a small sample
of physicians in three states [19]. Andrilla and colleagues
found that rural prescribers described their buprenor-
phine practice as rewarding and meaningful. However, a
survey of waivered physicians indicated that prescribers
rated their buprenorphine work as significantly less per-
sonally rewarding when compared to their general med-
ical practice [19]. To date, there have been no studies of
prescriber satisfaction with delivering XR-naltrexone as
a treatment for OUD. These gaps in the literature are
notable because there is a substantial literature regarding
global physician satisfaction, which is associated with
burnout, turnover intention, and intentions to leave the
practice of medicine [20–22]. In addition, research has
shown that physician satisfaction is associated with pa-
tients’ satisfaction [23, 24] as well as patients’ compli-
ance with medical recommendations [25].
The lack of comparisons in delivering of buprenor-
phine versus extended-release naltrexone is notable
given that implementation of the two medications may
have some differences. For example, research has dem-
onstrated major differences in the percentage of individ-
uals who are successfully inducted onto the medication,
with lower rates of successful induction for extended-
release naltrexone than buprenorphine [26]. There is
also some evidence of lower retention for extended-
release naltrexone [15, 27], and that buprenorphine, but
not extended-release naltrexone, being associated with
lower odds of opioid-related overdose [28]. It is un-
known if these challenges for initiation and retention
translate into lower prescriber satisfaction with deliver-
ing extended-release naltrexone relative to buprenor-
phine satisfaction.
The aim of the current study was to expand on our
prior work regarding buprenorphine satisfaction [19] by
exploring the satisfaction of prescribers delivering
buprenorphine as well as XR-naltrexone. In addition to
considering satisfaction with delivering both types of
MOUD, we sought to examine a new set of variables as
potential correlates of MOUD satisfaction, including
current MOUD patient census and prescribers’ percep-
tions of the larger organization. Delivery of MOUD re-
quires physicians to develop additional skills and
competence, as OUD can be a challenging condition to
treat. Patient census was conceived as a proxy measure
for competence and perceived effectiveness, as presum-
ably physicians would only be willing to take on more
patients if they felt they had the capacity and confidence
to effectively treat them. Similarly, tenure in the addic-
tion field and addiction-specific board certifications may
serve as indicators of competence, as greater years of ex-
perience and gaining specialized training in addiction
should be positively correlated with more developed
clinical skills. Previous research has shown that clini-
cians’ perceived effectiveness is positively associated with
job satisfaction [29]. Regarding the organizational envir-
onment, prior research on physician satisfaction has
shown the importance of positive relationships among
clinicians within organizations [30, 31] as well as the
negative impacts of high job demands and burdens [29].
Methods
Sample and data collection
Data were drawn from a cluster randomized clinical trial
(RCT) that sought to increase access to MOUD
(NCT02926482) in 37 organizations in Florida, Ohio,
and Wisconsin through a comparison of two sets of im-
plementation strategies [32]. Within these 37 organiza-
tions, the study sample consisted of 61 treatment units
within 31 specialty addiction treatment organizations
and 14 treatment units within 6 health systems. Using
procedures similar to a survey fielded in the first year of
the study [19], during the third year of this project, the
contact person for each organization participating in the
RCT forwarded invitations to MOUD prescribers within
these organizations to participate in a web-based survey.
Multiple reminders were sent to potential participants
about completing the survey, but no financial incentive
for survey completion was provided. Forty-one
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respondents completed the survey from June 2019 to
February 2020, representing 40 physicians and one nurse
practitioner. The University of Wisconsin’s institutional
review board approved all study procedures.
Measures
Items measuring prescriber satisfaction with providing
buprenorphine and XR-naltrexone treatment were
adapted from the Physician Worklife Survey [33].
Among those providing each MOUD, five items asked
about global satisfaction with their current buprenor-
phine work, and five items inquired about their current
XR-naltrexone work. For each item, response options
ranged from 1 (“strongly disagree”) to 5 (“strongly
agree”). In addition to considering each item separately,
mean scales of buprenorphine job satisfaction (α = 0.87)
and XR-naltrexone job satisfaction (α = 0.89) were calcu-
lated, after reverse-coding the negative valence items.
The survey measured several prescriber characteristics
as well as their perceptions of the organizational envir-
onment. Prescribers indicated whether they were waiv-
ered to prescribe buprenorphine (1 = yes, 0 = no) and
whether their site provided XR-naltrexone (1 = yes, 0 =
no). Waivered prescribers were asked about their current
buprenorphine census (i.e., number of patients currently
being treated with buprenorphine) and current waiver
limit (i.e., 30 patients, 100 patients, or 275 patients).
Using these two pieces of information, an additional
variable was constructed regarding the percentage of the
waiver currently used. For prescribers of XR-naltrexone,
current census of patients being treated with XR-
naltrexone was also reported. Prescribers were asked
about the following addiction-focused board certifica-
tions: Addiction Medicine by the American Board of
Addiction Medicine, Addiction Medicine by the Ameri-
can Board of Preventive Medicine, and Addiction Psych-
iatry by the American Board of Psychiatry and
Neurology. Responses were coded into those with addic-
tion board certification ( = 1) and those without certifi-
cation ( = 0). Four items measured perceptions of the
organizational environment, with responses ranging
from 1 (“strongly disagree”) to 5 (“strongly agree”).
These items focused on organizational commitment,
positive relationships with clinical staff, work overload,
and perceived respect by the organization. Demographic
characteristics included age, gender, and race (0 = white,
1 = all others).
Statistical analysis
First, descriptive statistics were calculated for all mea-
sures. Due to the small sample, analyses relied upon
Pearson’s product-moment correlations between the
measures of prescriber satisfaction and patient census,
physician experience, and perceptions of the
organizational environment. For the sub-sample who re-
ported being waivered and prescribing XR-naltrexone,
paired t-tests were used to test whether prescriber satis-
faction differed between the two medications. Given the
exploratory nature of the study, we did not correct for
multiple comparisons. Data were collected during an
organizational RCT in three states, so study condition of
the prescribers’ organization was examined using inde-
pendent samples t-tests and the three states were com-
pared by one-way analysis of variance. There were no
significant differences in buprenorphine satisfaction or
XR-naltrexone satisfaction by study condition or by state
(results not shown).
Results
Among the 41 respondents, the average age was 51.0
(SD = 11.0), 37.5% (n = 15) were female, and the major-
ity identified as white (70.7%, n = 29). About 37.5% (n =
15) were board certified in an addiction specialty. Nearly
all of the respondents held the waiver to prescribe
buprenorphine (92.7%, n = 38). Of the waivered pre-
scribers, the most common waiver type was the 275-
patient waiver (44.7%, n = 17); 31.6% held the 100-
patient waiver (n = 12), and 23.7% held the 30-patient
waiver (n = 9). The average census of current buprenor-
phine patients among waivered prescribers was 56.4 (SD
= 57.0), but the average proportion of their waiver being
used was just 37.4% (SD = 24.8). About 78.1% of the
sample (n = 32) indicated that they provide XR-
naltrexone for OUD, and for these prescribers, the aver-
age census of patients currently receiving XR-naltrexone
for OUD was 20.7 (SD = 26.3).
Table 1 presents satisfaction with buprenorphine work
among waivered prescribers and satisfaction with XR-
naltrexone work among those offering this medication
to treat OUD. As seen in Table 1, physicians were gener-
ally satisfied with their work in delivering these two
types of MOUD. Satisfaction measures with positive va-
lences (e.g., personally rewarding) had means near 4.0,
indicating agreement, while items with negative valences
(e.g., frustration) had means near 2.0, indicating dis-
agreement. For the sub-sample of prescribers offering
both medications (n = 31), paired t-tests indicated there
was only one significant difference in the five items, such
that prescribers more strongly endorsed buprenorphine
work being a source of frustration (mean = 2.3, SD =
0.9) than XR-naltrexone work (mean = 2.0, SD = 0.8, t =
-2.52, p = .02) (other results not shown).
Bivariate correlations between satisfaction with bupre-
norphine work, prescriber characteristics, and percep-
tions of the organizational environment are presented in
Table 2. Current number of buprenorphine patients was
associated with all five satisfaction measures, such that
prescribers with greater numbers of patients more
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strongly endorsed the positive valence questions and re-
ported lower frustration and unmet expectations. How-
ever, the measure of the proportion of waiver used was
not associated with any of the buprenorphine satisfac-
tion measures. Regarding perceptions of the
organizational environment, prescribers who would rec-
ommend the treatment center to colleagues more
strongly endorsed the positive valence items while
reporting lower frustration and unmet expectations.
Good relationships with clinical staff were also associ-
ated with the satisfaction items, with the exception of
the item regarding unmet expectations. Feeling
overburdened by clinical responsibilities was only associ-
ated with one of the five satisfaction items (i.e., satisfied
with current practice), while feeling more valued by the
organization was correlated with greater endorsement of
buprenorphine work being rewarding and lower en-
dorsement of frustration. There were no differences in
satisfaction with buprenorphine work by tenure in the
addiction field or by addiction-specific board
certification.
Next, the buprenorphine work satisfaction items were
combined into a mean scale of overall satisfaction, and
the prescriber characteristics and perceptions of the
Table 1 Descriptive statistics of physician satisfaction with buprenorphine (n = 38) and XR-naltrexone work (n = 32)
Buprenorphine Work XR-Naltrexone Work
Mean (SD) % Agree or Strongly Agree (n) Mean SD % Agree or Strongly Agree (n)
I find my present work personally rewarding. 4.2 (0.7) 84.2% (32) 4.1 (0.9) 81.3% (26)
Overall, I am pleased with my work. 4.2 (0.6) 89.5% (34) 4.1 (0.8) 87.5% (28)
Overall, I am satisfied with my current practice. 4.1 (0.7) 83.8 % (31) 3.9 (0.8) 84.4% (27)
My current work is a major source of frustration. 2.2 (0.9) 13.2 % (5) 2.0 (0.8) 3.1% (1)
My work in this practice has not met my expectations. 2.1 (0.8) 7.9% (3) 2.1 (1.0) 12.5% (4)
Mean satisfaction scale 4.0 (0.6) 4.0 (0.7)
Notes. Items were adapted from the Physician Worklife Survey (Williams et al., 1999), with response options ranging from 1 = strongly disagree to 5 = strongly
agree. Negative valence items were reverse-coded for the mean scales
Table 2 Pearson’s product-moment correlations between patient volume, prescriber characteristics, organizational environment, and
buprenorphine satisfaction















situation is a major
source of frustration.
My work in this
buprenorphine




0.36* 0.39* 0.35* -0.41* -0.34*
Proportion of waiver used
(i.e., current number
divided by waiver limit)
0.03 0.12 0.30 -0.21 -0.28
Tenure in addiction
treatment field
-0.16 -0.20 -0.14 0.14 0.04
Certified in an addiction
specialty
0.09 0.20 -0.04 -0.11 0.07
I would recommend this
treatment center to
colleagues.
0.53*** 0.59*** 0.47** -0.43** -0.34*
I have a good
relationship with the
clinical staff of this
organization.
0.62*** 0.63*** 0.41* -0.45** -0.28




-0.24 -0.25 -0.38* 0.31 0.27
I feel valued and
respected by this
organization.
0.36* 0.27 0.13 -0.35* -0.23
*p < .05, **p < .01, ***p < .001 (two-tailed tests)
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organizational environment were re-examined. Of the
eight variables, four were significantly associated with
overall buprenorphine work satisfaction. Prescribers
reporting a greater number of patients (r = .46, p =
.006), those who would recommend the center to others
(r = .56, p < .001), and those reporting positive relation-
ships with staff (r = .56, p < .001) reported significantly
greater overall buprenorphine work satisfaction. Pre-
scribers who more strongly endorsed feeling overbur-
dened reported lower overall buprenorphine satisfaction
(r = -.37, p = .02).
Table 3 presents bivariate correlations between the
satisfaction items for XR-naltrexone work, patient vol-
ume, prescriber characteristics, and perceptions of the
organizational environment. Overall, there were few sig-
nificant correlations. The current number of XR-
naltrexone patients was only correlated with the negative
valence items, such that prescribers with more patients
reported significantly lower levels of frustration and un-
met expectations. Tenure in the addiction field was
negatively associated with being pleased with and being
satisfied with XR-naltrexone work, such that prescribers
with greater tenure reported lower satisfaction. None of
the organizational environment items were correlated
with the items for XR-naltrexone work satisfaction.
When the five items were combined into an overall scale
of XR-naltrexone work satisfaction, none of the variables
were significantly associated with this scale.
Discussion
This study examined prescribers’ satisfaction with pro-
viding two types of MOUD, buprenorphine and XR-
naltrexone. We found that prescribers are generally sat-
isfied with providing these two MOUDs, which is im-
portant since prescriber dissatisfaction can lead to
turnover and impact intentions to leave the profession
[34, 35]. Ratings for the two MOUDs were remarkably
similar, which was somewhat surprising given the induc-
tion challenges [26] and shorter average retention that
occurs with extended-release naltrexone [15, 27]. How-
ever, the correlates of satisfaction differed between the
two medications, in that patient volume and some of the
organizational context measures were associated with
buprenorphine work satisfaction, but none of the vari-
ables were associated with XR-naltrexone work
satisfaction.
One notable finding was that the number of patients
was positively correlated with prescriber satisfaction with
delivering buprenorphine treatment. This magnitude of
the association between census and the scale of bupre-
norphine satisfaction represented an effect size in the
range of medium to large [36]. Questions remain about
the direction of causality. It may be that treating more
patients is an indicator of proficiency in or penchant for
delivering this type of MOUD, which may positively im-
pact satisfaction in treating this population. In other
types of medical care, such as surgical procedures, a
Table 3 Pearson’s product-moment correlations between patient volume, prescriber characteristics, organizational environment, and
injectable naltrexone satisfaction













naltrexone work is a
major source of
frustration.
My work in this
injectable naltrexone





0.26 0.17 0.17 -0.40* -0.37*
Tenure in addiction
treatment field
-0.27 -0.45* -0.38* -0.03 0.31
Certified in an addiction
specialty
0.21 0.19 0.01 -0.29 0.05
I would recommend
this treatment center to
colleagues.
0.23 0.14 -0.06 -0.29 -0.10
I have a good
relationship with the
clinical staff of this
organization.
0.24 0.15 -0.09 -0.32 -0.13
I feel overburdened
with my current clinical
responsibilities at this
organization.
0.11 0.01 0.08 0.02 -0.04
I feel valued and
respected by this
organization.
-0.08 -0.08 -0.12 -0.15 -0.07
*p < .05, **p < .01, ***p < .001 (two-tailed tests)
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positive relationship between patient volume and patient
outcomes is well-established [37, 38]. Treating more pa-
tients also provides more opportunities to observe pa-
tients entering remission and experiencing positive
changes in their lives, which may also be a source of sat-
isfaction. It may also be that prescribers who are more
satisfied are more willing to take on additional patients.
Future research should aim to replicate this finding in a
larger sample with longitudinal data to help to better
understand this association.
For buprenorphine work satisfaction, the associations
regarding positive relationships with clinical staff and
overly burdensome work demands align with prior re-
search on physician satisfaction [29–31]. These correla-
tions represented medium to large effect sizes [36].What
is puzzling, however, was that these measures of the
organizational context were not associated with XR-
naltrexone work satisfaction. One potential explanation
may be sample size, in that fewer prescribers offered
XR-naltrexone than buprenorphine. However, it may
also be that there are differences in how these two types
of MOUD are implemented in clinical settings, which
may then have implications for if or how the
organizational context may matter in terms of prescriber
satisfaction. Future research using qualitative semi-
structured in-depth interviews with prescribers may be
an important method for better understanding how
organizational context intersects with satisfaction in de-
livering different types of MOUD. In the current study,
qualitative data collection focused on the issue of
MOUD capacity-building from the perspective of
organizational champions of MOUD who were most
often in administrative positions [39]. The qualitative in-
terviews revealed novel facilitators and barriers that dif-
ferentiated organizations that made continuous
improvements in MOUD capacity from those that did
not. This ability to identify innovative factors inductively
is a key strength of qualitative methodology and points
to how in-depth interviews with prescribers could simi-
larly lead to novel insights regarding satisfaction with
delivering MOUD.
The study also provides insights into how the
provision of MOUD might impact prescriber reten-
tion patterns. For prescribers, higher volumes of
buprenorphine patients correlated with higher satis-
faction levels. Simply encouraging prescribers to pre-
scribe more buprenorphine will not likely lead to
higher satisfaction by itself. Future research should
seek to explore what leads to an individual physician
wanting to prescribe buprenorphine to more patients
and to create those working conditions that could
lead to greater use of buprenorphine as well as
greater satisfaction. For example, if a prescriber is ex-
pressing concerns regarding their confidence in using
buprenorphine, there may be value in engaging them
with an Extension for Community Healthcare Out-
comes (ECHO) session or a peer mentor. The positive
correlation between strong relationships with other
clinical team members and buprenorphine satisfaction
may indicate that a multi-discipline care model helps
to make delivering buprenorphine treatment more
meaningful and less burdensome. Our findings about
XR-naltrexone satisfaction and tenure in the field sug-
gest that perhaps use of XR-naltrexone could be en-
couraged for prescribers who are earlier in their
career. For those more advanced in their career, it
may be that additional supports are needed to assist
them with using this MOUD and appreciating its
benefits, as those with greater tenure in the addiction
field reported lower XR-naltrexone satisfaction.
Although this sample of prescribers is small, the find-
ings aligned with a number of studies that have reported
that most prescribers of buprenorphine are not fully util-
izing their capacity based on their waiver type [14, 40–
44]. A recent analysis documented that a small subset of
buprenorphine prescribers (~5 %) were responsible for
nearly half of US prescriptions over a two year period,
and even these high volume prescribers averaged about
124 patients per month, which was well below the 275
patient cap [45]. In this sample, prescribers were on
average using only about one-third of their capacity. Pre-
scribers treated even fewer patients with injectable nal-
trexone, a finding that is consistent with other studies
that have examined insurance claims data on utilization
[15]. Unused MOUD treatment capacity is concerning
given the scope of the ongoing opioid epidemic. Add-
itional research is needed to further elucidate the factors
associated with low utilization.
Several limitations to this study should be noted. First,
the sample was quite small, and the prescribers were re-
cruited from only three states. Our data collection strat-
egy relied upon a key point of contact forwarding the
survey invitations to prescribers, making it difficult to
ascertain a response rate. A separate survey of
organizational characteristics indicated a total of 65
waivered prescribers worked in these organizations, and
we received responses from 38 waivered prescribers
(58%). It is unknown if dissatisfied prescribers were less
likely to respond to the survey. Also, the findings are
from a cross-sectional survey which cannot establish
causality. In addition, this study was conducted in the
context of an RCT focused on expanding MOUD, so the
organizations recruited as sites may have cultures that
are more supportive of MOUD which may have implica-
tions for physician satisfaction. Finally, only a limited
number of constructs were included in the survey. Add-
itional domains may be associated with prescriber satis-
faction, such as challenges in obtaining reimbursement
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from insurers and stress experiences from concerning
patient behaviors (e.g., misuse and diversion of bupre-
norphine, treatment dropout). Personality factors may
also be correlated with prescriber satisfaction. Future re-
search should also consider whether some of the factors
that are associated with general job satisfaction are also
correlated with prescribers’ satisfaction in providing
MOUD.
While future research should examine these issues in a
larger, more generalizable sample, the study points to
potentially important directions for future research.
Continuing to examine additional factors associated with
prescriber satisfaction with MOUD may identify direc-
tions for intervention development, including strategies
to increase MOUD use and foster prescriber retention.
Furthermore, qualitative data collection may help to elu-
cidate why the factors associated with satisfaction
seemed to differ between the two types of medication.
Conclusions
In the context of the opioid epidemic, there are ongoing
concerns of shortages of prescribers of MOUD [46–48],
so satisfaction among those providing these evidence-
based practices is important. This sample of prescribers
reported general satisfaction with delivering buprenor-
phine and XR-naltrexone, and their ratings did not differ
between these two types of MOUD. There may be value
in encouraging prescribers with small caseloads to con-
sider expanding their MOUD practice, as our findings
suggest there may be a benefit for prescriber satisfaction
from treating more patients with MOUD, although more
research is needed to confirm this finding. Managers of
clinics should attend to supporting a positive
organizational climate, as measures of organization con-
text were associated with satisfaction in delivering
buprenorphine. Future research is needed to examine
multivariate models of satisfaction, to determine whether
MOUD dissatisfaction is associated with prescribers’ de-
implementing this service, and to develop interventions
that may reduce dissatisfaction.
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